Microfluidic Fabrication of Colloidal Nanomaterials-Encapsulated Microcapsules for Biomolecular Sensing by Zhang, Weixia et al.
Microﬂuidic Fabrication of Colloidal Nanomaterials-Encapsulated
Microcapsules for Biomolecular Sensing
Xi Xie,†,‡,§ Weixia Zhang,# Alireza Abbaspourrad,#,∇ Jiyoung Ahn,∥ Andrew Bader,‡ Suman Bose,‡,§
Arturo Vegas,‡,§ Jiaqi Lin,‡,§ Jun Tao,† Tian Hang,† Hyomin Lee,# Nicole Iverson,∥ Gili Bisker,∥
Linxian Li,‡,§ Michael S. Strano,∥ David A. Weitz,# and Daniel G. Anderson*,‡,§,○,⊥
†The First Aﬃliated Hospital, School of Electronics and Information Technology, Sun Yat-Sen University, Guangzhou 510275, China
‡David H. Koch Institute for Integrative Cancer Research, §Department of Chemical Engineering, ∥Department of Chemical
Engineering, and ⊥Harvard MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge,
Massachusetts 02139, United States
#School of Engineering and Applied Sciences, Department of Physics, Harvard University, Cambridge, Massachusetts 02138, United
States
∇Department of Food Science, Cornell University, Ithaca, New York 14853, United States
○Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United
States
*S Supporting Information
ABSTRACT: Implantable sensors that detect biomarkers in vivo are critical for early disease diagnostics. Although many
colloidal nanomaterials have been developed into optical sensors to detect biomolecules in vitro, their application in vivo as
implantable sensors is hindered by potential migration or clearance from the implantation site. One potential solution is
incorporating colloidal nanosensors in hydrogel scaﬀold prior to implantation. However, direct contact between the nanosensors
and hydrogel matrix has the potential to disrupt sensor performance. Here, we develop a hollow-microcapsule-based sensing
platform that protects colloidal nanosensors from direct contact with hydrogel matrix. Using microﬂuidics, colloidal nanosensors
were encapsulated in polyethylene glycol microcapsules with liquid cores. The microcapsules selectively trap the nanosensors
within the core while allowing free diﬀusion of smaller molecules such as glucose and heparin. Glucose-responsive quantum dots
or gold nanorods or heparin-responsive gold nanorods were each encapsulated. Microcapsules loaded with these sensors showed
responsive optical signals in the presence of target biomolecules (glucose or heparin). Furthermore, these microcapsules can be
immobilized into biocompatible hydrogel as implantable devices for biomolecular sensing. This technique oﬀers new
opportunities to extend the utility of colloidal nanosensors from solution-based detection to implantable device-based detection.
KEYWORDS: Microcapsules, microﬂuidic fabrication, nanosensors, biomolecular sensing
Point-of care systems and personalized medical devicesrequire implantable sensors that are able to continuously
detect and monitor analytes in vivo so that disease can be
detected for early diagnosis or real-time monitoring.1,2
Advances in nanomaterial-based sensors have the potential to
substantially improve disease diagnoses.3−6 In particular, many
types of colloidal nanoparticles,7−11 nanorods,3,12 carbon
nanotubes,4 and graphene13 have been investigated as optical
sensors. Many of these nanosensors exhibit diﬀerent types of
optical changes in response to a variety of cues such as
ﬂuorescence lifetime,14 spectrum,3,15 and polarization.16 To
achieve speciﬁcity in these responses, nanomaterials have been
conjugated to ligands that provide speciﬁc binding of analytes.
Upon target binding, the nanosensors generate15,17 or
amplify18,19 an optical responses. Some examples of previously
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studied optical sensing methods include ﬂuorescence,17
luminescence,20 and surface-enhanced Raman spectroscopy
(SERS)19 as well as surface plasmon resonance (SPR).3,15
Biomolecular detection assays using colloidal nanomaterials are
generally conducted in vitro, where targeting blood samples or
homogenized tissues are added to the aqueous solution of the
colloidal nanosensors. Successful applications have been
achieved in vitro for the detection of a variety of biomolecules
such as glucose,21−23 heparin,24 proteins,25 DNA,25,26 and
ions.25
Colloidal nanomaterials must be dispersed in solution phase
to function, and in general, two strategies have been
implemented to deliver these into the human body. One
option is to load colloidal sensors into a dialysis bag and
implant the resultant device;27,28 however, long-term in vivo
sensing with these approaches are still limited by biofouling and
ﬁbrosis to dialysis materials.1,28 Another strategy is to
incorporate the colloidal nanosensors into a biocompatible
hydrogel scaﬀold (Figure 1a), which can be surgically implanted
in human tissue for long-term sensing.29−31 However, direct
contact of colloidal nanosensors with the hydrogel matrix has
the potential to impact sensor activity (Supporting Information
S1).
Here, we develop colloidal nanosensors encapsulated in
microcapsules with a liquid core. The nanosensors were sealed
in the microcapsules but freely disperse throughout the internal
liquid core (Figure 1b). Biomolecules can diﬀuse through the
polymer shell of the capsules freely and interact with the
trapped nanosensors in the core, generating optical signals to
be detected as a result of target biomolecule-sensor binding.
These capsules can be further coated in a biocompatible
hydrogel to create an implantable device for biomolecular
sensing.
To demonstrate this design, polyethylene glycol (PEG)
microcapsules were fabricated with encapsulated nanosensors
using a glass capillary microﬂuidic technique.32 Here, we
demonstrate that this capsule fabrication methodology can
allow for tunable permeability speciﬁc to diﬀerent biomolecules
such as glucose, heparin, and streptavidin while retaining
encapsulated nanomaterials. In this study, two diﬀerent
functionalized nanosensors, quantum dots (QDs) and gold
nanorods (NRs), were successfully encapsulated and utilized to
speciﬁcally detect biomolecules such as glucose and heparin.
These capsules were further immobilized in calcium-alginate
hydrogels and retained sensing performance. These results
indicate that liquid-core microcapsules may be a versatile and
universal platform for encapsulating various colloidal nano-
sensors for sensing diﬀerent biomolecules.
Results. A glass capillary microﬂuidic technique was
employed to fabricate template double emulsion droplets
(water/oil/water), which were then polymerized to form
microcapsules by UV irradiation (Figure 2a).32 The capillary
microﬂuidic device was fabricated using three separate
capillaries: two tapered cylindrical capillaries, serving, respec-
tively, as injection and collection tubes were inserted and
aligned in the third square capillary.32 An aqueous solution of
nanosensors was injected through the injection tube as the
inner phase, and a dichloromethane (DCM) solution consisting
of 30% (v/v) photocurable monomer, polyethylene glycol
diacrylate (PEGDA), and 0.5% (v/v) photoinitiator, 2-hydroxy-
2-methyl-1-phenyl-1-propanone, was injected as the middle
phase. An aqueous solution containing 10% (w/w) poly(vinyl
alcohol) (PVA), which served as surfactant, was injected as the
outer phase. It focused the coﬂowing middle and inner ﬂuids
into a ﬂuid thread that then broke into double emulsion drops
(Figure 2b), which were further polymerized by UV irradiation
to form uniform microcapsules. Some solid beads were
generated during the fabrication process due to the rupture
of some double emulsion drops before UV irradiation. The
microcapsules were washed with water to remove the surfactant
and were puriﬁed to remove the solid beads based on density
diﬀerence.
Using this fabrication method, 5 nm diameter red ﬂuorescent
CdSe/ZnS quantum dots (emission wavelength of ∼655 nm)
Figure 1. (a) Colloidal nanosensors in bulk hydrogel matrix. Direct contact of colloidal nanosensors with the hydrogel matrix has the potential to
impact sensor activity. (b) Colloidal nanosensors encapsulated in microcapsules with a liquid core. The nanosensors were sealed in the microcapsules
but freely disperse throughout the internal liquid core. Biomolecules can diﬀuse through the polymer matrix freely and interact with the trapped
nanosensors, generating optical signals to be detected as a result of target biomolecule-sensor binding. Panel ii is the cross-section view of panel i.
Figure 2. Microcapsules fabrication. (a) Illustration of the capillary
microﬂuidic device for fabrication of microcapsules. The inner (red,
water phase containing nanosensors) and middle (green, oil phase
containing PEGDA monomer) ﬂuids were focused by the outer (blue,
water phase) ﬂuid to generate double emulsion droplets. (b) Optical
microscope image showing double emulsion droplet formation. (c)
Optical image of the as-fabricated microcapsules. (d) QDs (red) were
encapsulated in the capsules. (e) Capsule shells were stained with
green ﬂuorescent dye. (f) SEM images of dried microcapsules and (g)
the cross-section of the capsule shell was shown. Scale bar: 500 μm in
panels c−e and 200 μm in panel f.
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were encapsulated in the inner phase of PEG capsules. As
shown by optical image in the Figure 2c, the diameter of the
resultant capsules were ∼250 μm. Confocal ﬂuorescence
microscopy imaging indicates that the QDs were successfully
encapsulated and dispersed in the liquid cores (Figure 2d). It
should be noted that the PEGDA monomer used is water-
soluble and, hence, may diﬀuse into the inner phase (water)
from the middle phase (DCM). These PEGDA monomers
were then cross-linked by UV irradiation, forming some
condensed PEG polymer in the liquid core of the capsules,
which resulted in the dark spots observed in the liquid cores as
seen in the confocal ﬂuorescence images (Supporting
Information S2). In Figure 2e, the shells of the capsules were
stained with ﬂuorescein isothiocyanate (FITC), a green
ﬂuorescent dye. To prepare samples for imaging in scanning
electron microscopy (SEM), the capsules were dried under
ambient conditions. After drying, the collapsed capsules (Figure
2f) were sliced to determine the thickness of the capsule shells,
which were found to be ∼15 μm (Figure 2g).
The capsules were stable, and >99% remained intact over
one month (Figures 3a and S3). The permeation of QDs into
the interior of the capsules was studied by using a confocal
ﬂuorescence microscopy to evaluate whether QDs can diﬀuse
into capsules. Instead of encapsulating the QDs inside the
capsules, an aqueous solution of QDs was added from the top
medium to the capsules whose liquid cores initially only
Figure 3. Confocal ﬂuorescence images showing the PEG capsule permeability to QDs and diﬀerent biomolecules. (a) Capsules loaded with QDs
(red) were stable over 1 month. (b) QDs (red) were not able to diﬀuse into the microcapsules after the capsules were incubated with QD solution
for 1 month. (c) The microcapsules were permeable to glucose analog (green ﬂuorescence). (d−f) Real-time ﬂuorescence images showing glucose
analog (green ﬂuorescence) trapped inside the capsules were able to freely diﬀuse to the outer medium. (g) FRAP experiment to determine the
capsule permeation to glucose analog. (h,i) The QDs-loaded capsules (red) were permeable to heparin-FITC (green) within 1 h. (j) Streptavidin-
FITC has limited diﬀusion into the capsules after incubation for 1 day. (k) Extended incubation of the capsules with streptavidin-FITC for 1 week
leaded to the permeation of streptavidin into the capsules eventually. Scale bar: 500 μm in panels a−f and h−k.
Figure 4. (a−f) The glucose sensing application of microcapsules loaded with QD-GOx nanosensors. (a) Schematic illustration of the QD-GOx
glucose nanosensors. (b,c) The ﬂuorescence intensity of QD-GOx decreases with reaction time when 10 mM glucose was added to the (a) QD-GOx
solution or the (b) QD-GOx-loaded capsules. (d) Real-time (0−30 min) confocal ﬂuorescence images showing the ﬂuorescence of the QD-GOx
loaded capsules was quenched when they were exposed to 10 mM glucose solution. (e) The QD-GOx solution and (f) the QD-GOx-loaded capsules
were used to detect a series of glucose solutions of diﬀerent concentration. Error bar indicates standard deviation of the mean (N = 3). (g) Optical
images of PEG hydrogel powders. (h) Glucose analog (green ﬂuorescence) was able to diﬀuse freely into the PEG hydrogel matrix within 10 min. (i)
QD-GOx (red ﬂuorescence) were dispersed in the PEG hydrogel. Glucose solution (1000 mM) was added to the hydrogel (j) but induced little
change on the ﬂuorescence intensity of the QD-GOx. (k) Schematic illustration of the gold NR-GOx glucose nanosensors. (l) Schematic illustration
of the gold NR-NH2 heparin nanosensors. (m) The SPR band changing of the NR-GOx solution and the NR-GOx-loaded capsules after exposure to
100 mM glucose for 6 h. (n) The SPR band changing of the NR-NH2 solution and the NR-NH2-loaded capsules after exposure to 0.1 mg/mL
heparin for 3 h. Scale bar: 500 μm in panels d and g−j.
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contained water without any QDs (Figure S3). The QDs were
not able to diﬀuse into the capsules, as the interiors of the
capsules remained dark even after exposed to the QDs solution
for one month (Figure 3b). Only a few of the capsules (<0.1%)
ruptured leading to QDs diﬀusion into their interiors (Figure
S3). These results indicate that the PEG shell of the capsule can
prevent the QDs from diﬀusing through the capsule boundary,
demonstrating that QDs can be encapsulated inside the
capsules without leaking out.
The permeation of biomolecules into the interior of the
capsules was determined by exposing the capsules to the
aqueous solution of biomolecules (Figure S4). To test the
permeation to glucose molecule (MW ≈ 180 Da), a ﬂuorescent
glucose analog, 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-
Amino)-2-deoxyglucose (2-NBDG, MW ≈ 342 Da) was used
for these studies.33 As shown by the results in Figure 3c,
ﬂuorescent intensity of the interior of the capsules was as bright
as the outer aqueous phase after 2-NBDG was added to the
capsules for 1 min, which suggests the ﬂuorescent glucose
analog can diﬀuse freely through the capsule shells (Figure S5).
In reverse, if the outer ﬂuorescent medium was removed and
replaced with phosphate-buﬀered saline (PBS) solution that
contained no glucose analog, the ﬂuorescent intensity was
initially brighter inside the capsules (Figure 3d) but rapidly
decreased to the similar intensity level as the outer medium
within 10 min (Figures 3e,f and S5). This result suggests that
the glucose analog trapped inside the capsules can readily
diﬀuse through the capsule shell to the outer medium. In
addition, the capsule permeability was demonstrated via
ﬂuorescence recovery after photobleaching (FRAP).34 In this
experiment, glucose analog was allowed to diﬀuse into the
capsules, and then the interior region of a capsule was exposed
to an intensive laser pulse to locally photobleach the glucose
analog that was trapped in the capsule. After photobleaching,
the unbleached “fresh” glucose analog in the outer medium
gradually diﬀused into the capsule, which resulted in the
recovery of interior ﬂuorescence as a function of time (Figure
3g). Based on this ﬂuorescence recovery experiment, the
permeability to glucose analog can be calculated to be 1.35 ±
0.25 μm/s (Figure S5).35
The capsules’ permeability to biomolecules of a larger sizes,
such as heparin (MW ≈ 10 kDa, FITC-labeled) and
streptavidin (MW ≈ 60 kDa, FITC-labeled), was also
determined. As shown in Figure 3h,i, these capsules allowed
heparin to diﬀuse into their interiors within 1 h (Figure S5).
However, the streptavidin−FITC protein did not rapidly to
diﬀuse into the capsules after 1 day (Figure 3j). Extended
exposure of the capsules to the aqueous solution of streptavidin
for 1 week allowed permeation of streptavidin into the capsules
(Figure 3k).
To evaluate if these liquid-core capsules can be utilized for
biomolecular sensing, several types of nanomaterials (QDs or
gold NRs) were made responsive to glucose or heparin and
encapsulated in the capsules.8,22,24,36 The design of QD glucose
sensors is based on the strategy developed by Cao et al.,8 in
which glucose oxidase (GOx) was covalently conjugated to the
CdSe/ZnS QDs (QD-GOx). The sensing mechanism is based
on the ﬂuorescence quenching of CdSe/ZnS QDs by H2O2
produced from the GOx-catalyzed oxidation of glucose (Figure
4a). Due to the electron hole traps on QDs serving as the
acceptor, the electron-transfer reaction occurs readily when
H2O2 interacts with the surface of the QDs, leading to the
formation of nonﬂuorescent CdSe anion.8 The ﬂuorescent
intensity of the QD-GOx decreases with reaction time in the
presence of glucose (red curve in Figure 4b), and these sensors
can detect glucose concentration as low as 1 mM (Figure S6),
within the sensitivity range of general glucose sensors for
diabetes diagnostics.27,37
QD-GOx sensors were encapsulated in the microcapsules as
described above. When the capsules were exposed to a 10 mM
glucose solution, the ﬂuorescent intensity of the encapsulated
QD-GOx decreases with time (red curve in Figure 4c). The
real-time images of glucose-induced ﬂuorescence quenching of
QD-GOx inside the capsules were shown in Figure 4d. This
result indicates that the glucose can readily diﬀuse into the
capsules and was then catalyzed by the GOx on the QDs’
surface, producing H2O2 that quenched the ﬂuorescence of
QDs (Figure S6). In a separate experiment, the QD-GOx
solution, or the QD-GOx-loaded capsules interacted with a
series of glucose solutions of diﬀerent concentrations (0, 5, 10,
20, and 40 mM) for a ﬁxed reaction time of 30 min (Figure 4e
and 4f). For both QD-GOx solution and the QD-GOx-loaded
capsules, the ﬂuorescence intensity decreased as the concen-
tration of glucose increased. For the QD-GOx solution, the
relative reduced ﬂuorescence intensity is closely proportional to
the concentration of glucose in the range of 0−8 mM (Figure
S6) and gradually reaches saturation after concentration >10
mM. For the capsules, the relative reduced ﬂuorescence
intensity increased with the increasing glucose concentration
up to 20 mM and then reached saturation. These results
demonstrate the potential application for these QD-GOx-
loaded capsules as a quantitative tool to measure glucose
concentration.
To evaluate the importance of dispersing the QD-GOx
nanosensors in liquid phase within the capsules, control
experiments were conducted by testing the sensing perform-
ance of QD-GOx nanosensors dispersed in PEG hydrogel
matrix. The capillary microﬂuidic technique is not suitable to
incorporate the nanosensors in solid beads because the
nanomaterials have poor dispersity in oil phase such as DCM
(Figure S7). Therefore, the QD-GOx nanosensors were directly
incorporated in PEG bulk hydrogel by mixing the QD-GOx
with 30% (v/v) PEGDA and 0.5% (w/w) photoinitiator,
Irgacure 2959, in water, and then the PEGDA was cross-linked
via UV irradiation to form hydrogel. The bulk hydrogel was
crushed into smaller powders to reduce the distance of mass
transportation from outer medium into it.
To test the permeability of the bulk hydrogel or hydrogel
powders to biomolecules, ﬂuorescent glucose analog or
heparin-FITC was added to them and incubated for 10 min
(Figure S7). Fluorescence was observed within the hydrogel
from the confocal ﬂuorescence images, which suggests these
biomolecules can diﬀuse into the PEG hydrogel freely (Figure
4g,h). However, the QD-GOx-loaded hydrogel showed limited
capability to detect the presence of glucose (Figure S7). The
ﬂuorescence of the QD-GOx changed very little over 30 min
after 1000 mM glucose was added to the bulk hydrogel or
hydrogel powders (Figure 4i,j). These results suggest the
sensing performance of QD-GOx was negatively aﬀected due to
the direct contact of QD-GOx with PEG polymer, and hence,
dispersing the nanosensors in liquid cores of capsules is crucial
for maintaining their sensing performance.
To evaluate the utility of this approach with other
nanosensors for detecting diﬀerent biomolecules, in addition
to the QD-GOx glucose sensors, another two types of sensors
based on gold NRs (length ∼40 nm) were tested (Figure 4k,l).
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In the ﬁrst example, gold NRs were designed to be responsive
to glucose by conjugating NRs with GOx (NR-GOx) according
to the method developed by Radhakumary et al. (Figure
4k).22,36 Glucose can be converted by GOx to produce gluconic
acid and H2O2 that brings down the ζ potential of the NRs,
which induces NRs aggregation and changing of their SPR peak
(Figure 4m solution). These NR-GOx sensors were encapsu-
lated in PEG capsules. Although the gold NRs lack visible
ﬂuorescence for testing their permeation to the microcapsules,
we hypothesized that the capsule shells should prevent the NRs
from leaking out because the size of NR is much larger than
QDs’. The SPR band changing of the NR-GOx-loaded capsules
was shown in Figure 4m capsules, in which the SPR peak
(absorbance maxima at 620 nm) of the NR-GOx changed after
the capsules were exposed to 100 mM glucose for 6 h.
In a separate experiment, gold NRs were designed to be
responsive to heparin by conjugating NRs with amine groups
(NR−NH2) based on the technique developed by Cao et al.
(Figure 4l),24 in which the heparin-amine binding induces
aggregation of the gold NRs leading to the changing of SPR
absorption band (Figure 4n-solution). The SPR band changing
of the NR−NH2-loaded capsules was shown in Figure 4n
capsules, in which the SPR peak (absorbance maxima at 660
nm) of the NR−GOx became ﬂatter after the capsules were
exposed to 0.1 mg/mL heparin for 3 h. These results indicate
utility of liquid core microcapsules loaded with diﬀerent
nanosensors for sensing various biomolecules.
Implantation in the body further requires that the surface of
the capsule exposed to the body is biocompatible and resistant
to biofouling. Toward this end, the QD-GOx-loaded capsules
were embedded in calcium alginate hydrogel (Figure 5a), which
has been previously evaluated in vivo various implantation
settings.38,39 The capsules were initially mixed with an aqueous
solution of alginate (1.4%), followed by adding 2.4% Ca2+
solution to cross-link the alginate. As shown in the 3D-
converted confocal image (Figure 5b), the QD-GOx-loaded
capsules (red) distributed at diﬀerent Z-planes within the
hydrogel. Glucose analog was able to diﬀuse freely through the
Ca2+-alginate hydrogel into the capsules (Figure S8). When 10
mM glucose was added to this capsule hydrogel, the QD-GOx
within the capsule responsively showed reduced ﬂuorescence
intensity with increasing reaction time (Figure 5c−f). There-
fore, this capsule-loaded hydrogel can demonstrate their
function for glucose sensing. In contrast, if the QD-GOx
nanosensors were directly loaded in Ca2+-alginate hydrogel, the
QD-GOx were loosely trapped in the hydrogel and tended to
release to the outer medium over several hours (Figure S9).
Conclusions. In this report, liquid core microcapsules were
developed and evaluated for their utility as encapsulation
systems for colloidal nanosensors. Microcapsules were
fabricated using a capillary microﬂuidic technique, and colloidal
nanomaterials were encapsulated. The microcapsules allow
permeation of diﬀerent biomolecules such as glucose and
heparin but prevent the encapsulated nanomaterials inside from
leaking out. By encapsulating glucose or heparin-responsive
nanosensors, the capsules were able to demonstrate corre-
sponding sensing functionalities. In addition, the microcapsules
can be further coated in hydrogels, potentially facilitating their
compatibility with the body while preserving sensing function.
The nanosensors-loaded microcapsules developed in this
work demonstrate a novel integrated platform to detect
biomolecules by utilizing the optical sensing capabilities of
colloidal nanomaterials. We expect that a large variety of
colloidal nanosensors can be incorporated using this technique
for detecting a wide range of biomolecules. As proof of concept,
QD and gold NR sensors that only allow one-time sensing were
employed in this work, while the using of more sophisticated
nanosensors with repeatable detections, fast response, and high
sensitivity and with near-infrared spectrum for deeper tissue
penetration may enable its use as an implantable sensor for
disease management in vivo.
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Figure 5. (a) Schematic of the microcapsules immobilized in hydrogel
scaﬀold. Biomolecules are allowed to diﬀuse through the hydrogel and
the capsules to interact with the nanosensors inside the capsules. (b)
3D-converted confocal ﬂuorescence image showing microcapsules
(red) were immobilized in Ca2+−alginate hydrogel and distributed at
diﬀerent Z-planes. (c) Optical image of capsules embedded in the
hydrogel. (d−f) Real-time confocal ﬂuorescence images (at 10, 20, and
30 min) showing the ﬂuorescence of QD-GOx (red) inside the
capsules were quenched after 10 mM glucose was added to the
hydrogel. Scale bar: 500 μm in panels b−f.
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